Acadia Healthcare (ACHC) Expected to Announce Earnings on Wednesday

Acadia Healthcare (NASDAQ:ACHC) is anticipated to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Acadia Healthcare to post earnings of $0.03 per share and revenue of $800.0990 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 9:00 AM ET.

Acadia Healthcare Stock Down 2.1%

Shares of ACHC stock opened at $16.42 on Wednesday. Acadia Healthcare has a 12 month low of $11.43 and a 12 month high of $42.85. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.73. The firm has a market cap of $1.51 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 4.77 and a beta of 0.89. The stock has a 50 day moving average of $14.07 and a 200-day moving average of $18.59.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN increased its holdings in Acadia Healthcare by 208.9% during the 4th quarter. Wells Fargo & Company MN now owns 2,233 shares of the company’s stock valued at $32,000 after purchasing an additional 1,510 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Acadia Healthcare by 54.8% during the second quarter. EverSource Wealth Advisors LLC now owns 1,404 shares of the company’s stock worth $32,000 after purchasing an additional 497 shares during the last quarter. Aristides Capital LLC acquired a new stake in shares of Acadia Healthcare in the fourth quarter valued at $196,000. Prudential Financial Inc. raised its holdings in shares of Acadia Healthcare by 21.9% in the second quarter. Prudential Financial Inc. now owns 9,903 shares of the company’s stock valued at $225,000 after buying an additional 1,780 shares during the last quarter. Finally, Glenmede Investment Management LP lifted its position in Acadia Healthcare by 15.6% during the 3rd quarter. Glenmede Investment Management LP now owns 11,379 shares of the company’s stock worth $282,000 after buying an additional 1,532 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ACHC shares. Royal Bank Of Canada cut their target price on shares of Acadia Healthcare from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, January 14th. TD Cowen reaffirmed a “reduce” rating on shares of Acadia Healthcare in a research report on Friday, January 16th. KeyCorp reduced their target price on shares of Acadia Healthcare from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft lowered their price target on Acadia Healthcare from $33.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, December 3rd. Finally, UBS Group reduced their price objective on Acadia Healthcare from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $18.62.

About Acadia Healthcare

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.